{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vilazodone", "query": { "intervention": "vilazodone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vilazodone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T11:15:42.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05422612", "title": "Department of Defense PTSD Adaptive Platform Trial - Master Protocol", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post Traumatic Stress Disorder" ], "interventions": [ { "name": "Intervention A Fluoxetine Hydrochloride (HCl)", "type": "DRUG" }, { "name": "Intervention A Placebo", "type": "DRUG" }, { "name": "Intervention B Vilazodone Hydrochloride (HCl)", "type": "DRUG" }, { "name": "Intervention B Placebo", "type": "DRUG" }, { "name": "Intervention C Daridorexant", "type": "DRUG" }, { "name": "Intervention C Placebo", "type": "DRUG" }, { "name": "Intervention D SLS-002", "type": "DRUG" }, { "name": "Intervention D Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Coalition for Adaptive Research", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 800, "start_date": "2023-11-02", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 9, "location_summary": "Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Tripler AMC", "state": "Hawaii" }, { "city": "Fort Thomas", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05422612" }, { "nct_id": "NCT00644358", "title": "A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "vilazodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 616, "start_date": "2007-12-31", "completion_date": "2009-05-31", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 38, "location_summary": "Garden Grove, California • San Diego, California • Torrance, California + 34 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00644358" }, { "nct_id": "NCT02893371", "title": "Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Lamotrigine", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Oxcarbazepine", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Fluoxetine / Olanzapine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Lurasidone", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Mirtazapine", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Desvenlafaxine", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" }, { "name": "Doxepin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1037352, "start_date": "2016-09", "completion_date": "2019-06-30", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893371" }, { "nct_id": "NCT01473394", "title": "Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Dose-matched placebo", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 518, "start_date": "2011-12", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-04-03", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 14, "location_summary": "Beverly Hills, California • Encino, California • New Port Beach, California + 11 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "New Port Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473394" }, { "nct_id": "NCT01844115", "title": "Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 415, "start_date": "2013-04-30", "completion_date": "2014-03-31", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844115" }, { "nct_id": "NCT01916824", "title": "Effects of Treatment on Decision-making in Major Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder", "Healthy Controls" ], "interventions": [ { "name": "Any FDA Approved Antidepressant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 53, "start_date": "2013-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01916824" }, { "nct_id": "NCT02015546", "title": "Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder (MDD)" ], "interventions": [ { "name": "Vilazodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 70, "start_date": "2012-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-04-16", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02015546" }, { "nct_id": "NCT00683592", "title": "Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "vilazodone", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 481, "start_date": "2008-03", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2010-10-27", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 9, "location_summary": "Newport Beach, California • Bradenton, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00683592" }, { "nct_id": "NCT01469377", "title": "Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Cariprazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 819, "start_date": "2011-12-15", "completion_date": "2013-12-12", "has_results": true, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 39, "location_summary": "Garden Grove, California • National City, California • Oceanside, California + 34 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01469377" }, { "nct_id": "NCT01608295", "title": "Vilazodone for Treatment of Geriatric Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Vilazodone; Viibryd", "type": "DRUG" }, { "name": "Paroxetine; Paxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 65, "start_date": "2012-07", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-09-02T11:15:42.812Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01608295" } ] }